Helping managed care executives succeed every day.

Joined July 2009
3,111 Photos and videos
We're launching the Health System Executive Summit—uniting exec, clinical, pharmacy & policy leaders for focused conversations on the issues shaping healthcare delivery. Register today: hubs.ly/Q04lfBfy0
18
Migraine is the #1 cause of disability in young women globally — so why is it barely mentioned in women's health policy conversations? hubs.li/Q04lftrG0
19
Can AI replace a doctor's eye when it comes to skin cancer? Not quite yet — at least not the most experienced ones, according to this new study published in JAMA Dermatology hubs.li/Q04l7Nyt0
43
A new machine learning model built from routine EHR data can identify adults at highest risk for type 2 diabetes up to 10 years before onset. hubs.li/Q04kXwx40
31
Nearly half of payers not covering GLP-1s for obesity say no price would change their minds on coverage, survey finds hubs.li/Q04kChs-0
20
The difference between being physician-led in name and physician-led in practice is becoming increasingly visible and increasingly important to distinguish, according to Sam Starbuck, president of Priva Care Partners hubs.li/Q04kBTG20
1
28
Researchers have long studied HIV stigma. But a Boston University psychologist is asking a different question: what happens to the shame patients carry inside? Read the full interview here: hubs.li/Q04k9Lvn0
22
64% of providers say staffing shortages are reducing patient access, up from 57% just a year ago. And hiring alone is no longer enough to close the gap. hubs.ly/Q04j_72W0
21
Join us for a free webinar on June 18 to hear from expert leaders at Geisinger, USC Schaeffer Institute and Aradigm as they share insights on the economic realities shaping the next generation of #CGT. Register here 👉 hubs.li/Q04jNWDz0 #ManagedCare #HealthcareLeadership
40
#Vitiligo affects more than the skin. Experts explore psychosocial impacts and the role of traditional treatments like TCS, TCIs and phototherapy. Watch the episode to learn more: hubs.li/Q04g_rzq0 #ManagedCare
71
This is how the experimental pancreatic cancer drug daraxonrasib's "molecular glue" mechanism just doubled overall survival in metastatic pancreatic cancer. hubs.li/Q04jF95_0
30
Not everyone agrees on how far-reaching the impact will be, but the entire industry is watching. Direct-to-patient models and #PBMreform are front and center for #ManagedCare leaders. Read our newest report for the insights your strategy needs: hubs.li/Q04jDg0_0 #pharmacy
37
Could earlier use of bispecific antibodies change the treatment experience in #MultipleMyeloma? This video highlights potential benefits, including avoiding steroids and reducing #Neuropathy risk. Watch: hubs.li/Q04gCXKL0 #ManagedCare
1
38
CVS Caremark is bringing Zepbound (tirzepatide) back to its formularies Oct. 1 and removing the new-to-brand block on oral GLP-1 Foundayo (orforglipron) June 1. #GLP1 #ObesityMedicine #Zepbound hubs.li/Q04jgY460
1
120
We're partnering with AJMC® PBMI on a free webinar and bringing together a panel of industry experts who will examine reimbursement models, financial risk, policy developments & strategies for improving access to cell and gene therapies. Register today! hubs.li/Q04j2Y7F0
1
46
Biggest #A1C gains in the first 3 months. Critical re-engagement at 6 months. This episode explores how clinicians use structured follow-up and motivational interviewing to combat CGM fatigue and sustain progress. Watch Now: hubs.li/Q04g6ksC0 #ManagedCare #DiabetesCare
31
Eli Lilly just acquired 3 vaccine companies in one day. 💊 → Curevo: shingles vaccine w/ 50% fewer side effects → LimmaTech: targeting antibiotic-resistant bacteria → Vaccine Company: nanoparticle EBV vaccine (linked to 97% of MS cases) hubs.li/Q04hYXk30
1
87
The collision of #PBMReform and federal drug price controls sends ripple effects through every corner of #ManagedCare. See what the data signals for the year ahead in our newest report: hubs.li/Q04hS-kP0 #DrugPricing #PharmacyLeadership #FederalPolicy
41
Only 1 in 4 eligible adults receive lung cancer screening, despite overall gains in recent years. hubs.li/Q04hGvDT0
32